Spironolactone is a well known survival improvement agent for heart failure with reduced ejection fraction. Its use in heart failure with preserved EF was however controversial. The TOPCAT trial established the failure of spironolactone to improve mortality in patients with HFpEF. The visual abstract illustrates the trial salient features.
Want to read more posts?